WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia Khvorova, Ph.D., Chief Scientific Officer, is presenting at the 101st annual American Association for Cancer Research (AACR) Conference on April 19, 2010. The presentation will not be webcast.
